27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination
Arkenau, H.T., Voskoboynik, M., Infante, J., Brenner, A., Patel, M., Borazanci, E., Falchook, G., Molife, L.R., Pant, S., Dean, E., Pelosof, L., Jones, S., Rubino, C., McCulloch, W., Zhukova-Harrill,Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(15)30076-9
Date:
September, 2015
File:
PDF, 61 KB
english, 2015